Italy's Recordati to acquire Spanish drugmaker
In a second takeover deal this year, Italian drugmaker Recordati (RC: MI) says it has signed agreements to acquire 100% of the share capital of Laboratorios Casen Fleet, a Spanish pharmaceutical company with headquarters in Madrid and production facilities in Utebo, Zaragoza.
The value of the transaction (enterprise value) is of 93 million euros ($122.4 million), which will be funded from existing liquidity. The closing of the transaction is expected to take place in the following weeks. Recordati recently announced plans to buy 90% of Tunis-based Opalia Pharma, for an enterprise value of $48 million (The Pharma Letter July 25).
Main focus on gastroenterology product, led by Citrafleet
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze